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Structured Abstract: 30 
 31 
Objective: To evaluate the effectiveness of progestogen supplementation in improving 32 
clinical pregnancy rates in women undergoing fresh IVF cycles and to compare different 33 
routes, start times, durations and estrogen co-administration regimen. 34 
Design: Comprehensive systematic review and meta-analysis. 35 
Setting: University. 36 
Patients: Women undergoing fresh IVF cycles who did and did not receive progestogen 37 
supplementation. 38 
Intervention(s): Summary odds ratios (ORs) were calculated by binomial logistic 39 
regression. 40 
Main Outcome Measure(s): Clinical pregnancy rates. 41 
Results: 82 articles (26,726 women) were included. Clinical pregnancy rates were 42 
increased by intramuscular (OR=4.57; p<0.001), vaginal (OR=3.34; p<0.01), 43 
subcutaneous (OR=3.36; p<0.01) or oral (OR=2.57; p<0.05) progestogen 44 
supplementation versus no treatment. Greatest benefit was observed when progestogens 45 
were supplemented intramuscularly versus vaginally (OR=1.37; p<0.001). The optimal 46 
time to commence administration was between oocyte retrieval and embryo transfer 47 
(OR=1.31; p<0.01), with oocyte retrieval +1 day being most beneficial. Co-administration 48 
of estrogen had no benefit (OR=1.33; p>0.05) whether progestogens were co-49 
administered vaginally or intramuscularly. Clinical pregnancy rates were equivalent when 50 
progestogen supplementation was ceased after ≤3 weeks or continued for up to 12 weeks 51 
(OR=1.06; p>0.05). 52 
Conclusion: This broad-ranging meta-analysis highlights the need to re-evaluate current 53 
clinical practice.  The use of progestogens in fresh IVF cycles is substantially beneficial to 54 
clinical pregnancy. Critically, the use of intramuscular progestogens should not be 55 
dismissed, as it yielded the greatest clinical pregnancy rates. Pregnancy success was 56 
impacted by initiation of therapy, with one day after oocyte retrieval being optimal. There 57 
is little evidence to support co-administration of estrogen or prolonging progestogen 58 
treatment beyond three weeks.  59 
Keywords: (3-5) meta-analysis, progestogen, estrogen, luteal phase support, fresh IVF 60 
Capsule: Luteal phase deficiency commonly occurs after ovarian stimulation in women 61 
undergoing assisted reproduction. Progestogen supplementation is a routine and critical 62 
component for luteal phase support, however, the optimal regimen remains unresolved. 63 
 64 
65 
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Introduction 66 
Luteal phase deficiency is a common result of assisted reproductive technologies (ART) 67 
and is characterised by inadequate or inappropriate progesterone production. This 68 
inevitably compromises the successful establishment and maintenance of pregnancy, and 69 
has led to the critical requirement for luteal support protocols. Luteal phase deficiency has 70 
been attributed to diminished luteotrophic support from pituitary LH, reduced luteal 71 
steroidogenic capacity and/or premature luteolysis (1-3). Hence, the provision of 72 
exogenous progestogens to supplement endogenous progesterone production has become 73 
a routine component of ART. 74 
In recent years, there has been much debate as to whether the immediate transfer of 75 
“fresh” embryos or cryopreservation with subsequent transfer of frozen embryos confers 76 
the greatest pregnancy success for patients (4, 5). Indeed, elective freeze-all cycles have 77 
been widely advocated and adopted (6), with an anticipated improvement in endometrial 78 
receptivity thought to give rise to an improved pregnancy outcome (7). However, recent 79 
evidence suggests that whilst a freeze-all strategy is of benefit to women who are highly 80 
responsive to ovarian stimulation, it is not beneficial for those women with a low or 81 
intermediate response (8). Therefore, there is an ongoing need for the evaluation of luteal 82 
phase support in fresh IVF cycles. 83 
The potential supplementation regimens for luteal phase support following ART are 84 
numerous; progestogens are available in a number of formulations (of progesterone or 85 
synthetic progestins) and can be administered by nasal, rectal, vaginal, oral, subcutaneous 86 
or intramuscular routes alone, or via multiple routes in combination. Progestogen 87 
administration can commence before oocyte retrieval, on the day of oocyte retrieval or in 88 
the days soon afterwards, or on or around the day of embryo transfer. Supplementation 89 
can then be maintained for several weeks, until a positive urinary pregnancy test, until 90 
fetal heart pulsations have been observed or until week 12 of gestation or later (9). Luteal 91 
phase progestogens may also be co-administered with estrogen.  92 
While there is an agreed need for luteal phase support following ART (10), the choice of 93 
preparation, route of delivery, time at which to commence treatment and its duration 94 
remain a matter of debate (11, 12). The wide variation in clinical approach means that the 95 
choice of luteal phase support for couples undergoing ART is far from clear. Evidence from 96 
clinical practice suggests a current global preference for luteal phase support via vaginal 97 
progestogens in tablet form, administered from the day of oocyte collection and 98 
maintained for 8-10 weeks (9).  99 
The current study critically evaluates the efficacy of luteal phase support by analysing the 100 
impact of these complex treatment choices on pregnancy rates following fresh embryo 101 
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transfer via binomial logistic regression, with the aim of both influencing practice and 102 
providing an essential point of reference for patients. In contrast to previous meta-103 
analyses, our use of binomial logistic regression enables the synthesis of results from the 104 
numerous studies performed without control groups. This distinctive and robust statistical 105 
approach has the benefit of greatly broadening both the scope of questions answered and 106 
the number of study groups eligible for each comparison (13). This includes addressing 107 
largely overlooked and important questions or those with few existing RCTs (14), such as, 108 
determining the optimal day on which to commence progestogen supplementation.  109 
Recent commentary (11) has concluded that the luteal phase in ART is deserving of greater 110 
attention, such as provided by this analysis. Furthermore, whilst the clinical approach to 111 
luteal phase support may be becoming more consistent (9, 15), the suggested lack of 112 
evidence-based decision making (9) may ultimately limit pregnancy success or lead to 113 
women undergoing additional treatment for luteal phase support that is of little benefit.   114 
Methods 115 
 116 
Search strategy 117 
An extensive systematic literature search was performed using Google Scholar 118 
https://scholar.google.com/, PubMed https://www.ncbi.nlm.nih.gov/pubmed and Web of 119 
Science http://wok.mimas.ac.uk (last accessed April 2018). Searches were performed in 120 
English and included studies (excluding abstracts and conference proceedings) published 121 
between 1980 and January 2018. For this purpose, the principal search terms in the title, 122 
abstract or keywords were “progesterone supplementation” OR “progestogen 123 
supplementation” OR “luteal support” in conjunction with “vaginal” OR “intramuscular” OR 124 
“oral” OR “subcutaneous” OR “rectal”.  A separate search was conducted with the following 125 
terms “assisted reproductive technology or ART”, “in vitro fertilization or IVF”,  “intra-126 
cytoplasmic sperm injection or ICSI”,  or “fresh embryo transfer”. The references within 127 
these articles including any meta-analysis were scrutinised for any additional articles. 128 
These search results were subsequently combined to yield a total of 517 articles (excluding 129 
duplicates) (Supplementary Fig 1).  130 
Selection of articles: methodology and criteria 131 
Following the PRISMA guidelines (16), the title, abstract and keywords were screened to 132 
confirm that the article was within subject remit and this excluded 327 articles (e.g.  133 
animal models). Then, the full text of each manuscript was obtained and reviewed. For 134 
articles to be included, the following inclusion criteria were assigned: 1) included sub-135 
fertile women (undefined or defined aetiology) undergoing ART with fresh embryo 136 
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transfer; 2) involved ovarian stimulation; 3) included an evaluation of pregnancy outcomes 137 
between two groups of women, either progestogen versus untreated control group, or 138 
comparing at least 2 different regimens of luteal support involving progestogen; 4) 139 
included pregnancy outcome represented as clinical pregnancy (e.g. presence of a 140 
gestational sac, with or without a fetal heartbeat on ultrasonography) as defined in the 141 
original manuscript.  142 
Articles were excluded for the following reasons: 1) assignment of progestogen treatment 143 
occurred after a positive HCG pregnancy test, 2) the only luteal support was HCG 144 
treatment; 3) studies involved frozen or donor oocyte cycles. A total of 108 articles were 145 
excluded, resulting in 82 articles submitted to the meta-analysis (Supplementary Fig 1).  146 
Assessing the risk of bias  147 
Two authors (RSR & KJW) independently assessed the risk of bias in each included article 148 
across several domains according to previous criteria (10); random sequence generation, 149 
allocation concealment, blinding of participants and personnel, blinding of outcome 150 
assessment, incomplete outcome data, selective reporting and other potential sources of 151 
bias (e.g. apparent variations in patient management or embryo quality between arms). 152 
Studies were classified as being at low, high or unclear risk of bias and the risk of bias 153 
analysis was used to generate a risk of bias summary figure (Supplementary Fig 2) and 154 
graph (Supplementary Fig 3).  155 
In order to mimimize any risk of bias across studies and in recognition of the difficulty of 156 
identifying publication bias and selective reporting, a comprehensive and broad-ranging 157 
systematic literature search for eligible studies was conducted. The articles were 158 
thoroughly interrogated for any duplication of data. 159 
Data collection process 160 
Data extraction was performed independently by two reviewers (AM & RSR) and 161 
discrepancies were resolved by discussion with a third reviewer (KJW). The following data 162 
were extracted from each article: route of progestogen administration, dose of 163 
progestogen and duration of progestogen treatment, the time when progestogen 164 
supplementation commenced and the presence or absence of estrogen co-treatment. 165 
Clinical pregnancy was considered the primary pregnancy outcome, with additional data 166 
on live birth tabulated when given. Additional extracted information included 167 
country/region of origin, publication date, number of patients, mean age of participants, 168 
type of ART procedure (e.g. IVF or ICSI or combination), and other treatment information 169 
including controlled ovarian stimulation protocol and ovulation trigger. 170 
  171 
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Classification of study groups 172 
Route of administration: The relative benefit of the different routes of progestogen 173 
administration was compared. The most commonly employed routes were intramuscular 174 
(IM) injection and vaginal pessary. However, other reported routes included oral, rectal 175 
and subcutaneous (SC) injection. There were several articles where no luteal support (N=8 176 
study groups) was administered and this control group was used as the reference in the 177 
initial analyses; in the later analyses, the vaginal route of administration was used as the 178 
comparator. The dose of progestogen was not analysed since it was intrinsically linked to 179 
route and further sub-divisions created groups with too few women. 180 
Time to commence supplementation: A key component of the meta-analysis was to 181 
investigate the effect of the time at which progestogen supplementation commenced. The 182 
start time of each treatment was classified into one of five groups; (1) before oocyte 183 
retrieval; (2) on the day of oocyte retrieval (at oocyte retrieval or evening of); (3) between 184 
oocyte retrieval and embryo transfer; (4) on the day of embryo transfer (ET); (5) after 185 
embryo transfer. In this analysis, the comparator was the control group which received no 186 
luteal support.  187 
In a subsequent analysis, study groups were further categorised as progestogen 188 
supplementation that commenced (1) at oocyte retrieval (the day and evening of), or on 189 
(2) the first, (3) second and (4) third day after oocyte retrieval. Most articles detailed this 190 
information directly, however in several articles this was determined utilising other 191 
information such as the oocyte retrieval to embryo transfer time. If there was insufficient 192 
information to state the exact day, then this study group was excluded from this analysis.  193 
Estrogen treatment: For this analysis, only articles which included a direct estrogen 194 
treatment comparison were included. All study groups which received estrogen as part of 195 
the luteal phase support were coded as treated, while the others were incorporated as the 196 
control comparator. The route of estrogen treatment (oral, transdermal patch or vaginal) 197 
and its timing (around oocyte retrieval or around embryo transfer) was not considered.  198 
Duration of progestogen supplementation: The study groups were classified based on 199 
whether progestogen supplementation treatment was 3 weeks or less, or greater than 3 200 
weeks. The cut-off at 3 weeks was selected as the approximate time of HCG pregnancy 201 
diagnosis and there was a natural stratification in the studies at 3 weeks of treatment.  202 
Sample size calculation 203 
The sample size for a binomial test (two-sided) was calculated with the overall mean 204 
clinical pregnancy rate of 37% being used as the reference. Thus, at a significance level 205 
of 0.05 with a 90% power of detection, the number of women in each study group required 206 
to detect: 1) an increase of 5 percentage points from the reference rate was 2000, 2) an 207 
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increase of 10 percentage points was 510 and 3) an increase of 15 percentage points was 208 
229. Alternatively, if all women (n=26,726) were included then a 2 percentage point 209 
change could be detected. 210 
Statistical analysis 211 
The statistical approach utilised was binominal logistic regression. The “number of 212 
subjects” was the total number of women who were treated within that study, the “number 213 
of successes” was the number of women with a confirmed clinical pregnancy or live birth 214 
and “the model fitted” was the factor (e.g. route or start time) that was being compared. 215 
The dispersion parameter was set to estimate the residual mean squares of fitted model. 216 
The analysis was performed using GenStat 19th Edition (Hemel Hempstead, UK). The data 217 
are presented as odds ratio (OR) with 95% confidence intervals (CI) alongside the number 218 
of study groups (N) and women (n). The use of binomial logistic regression meant that no 219 
estimate of heterogeneity between articles (i.e. estimation of I2) was feasible. 220 
Comparison between different routes of administration: In the initial analysis, the different 221 
routes of administration (IM, oral, rectal, SC and vaginal) were compared to the control 222 
(no luteal support) group. A further 11 study groups where progestogen was 223 
simultaneously administered by multiple routes (i.e. IM plus vaginal) were excluded from 224 
this analysis. None of the control study groups reported live births, thus the effects of 225 
route of administration on live births were not analysed.  226 
Comparison between the different times at which progestogen supplementation 227 
commenced: The effects of the different start times (before oocyte retrieval, at oocyte 228 
retrieval, between oocyte retrieval and ET, at ET and after ET) on clinical pregnancy rate 229 
were compared to the control group. For the effects on live birth rates, the start times 230 
were compared to commencing supplementation at oocyte retrieval, as no live birth rates 231 
were reported in the control group. 232 
Comparison between different start times when progestogen was given via either 233 
intramuscular or vaginal routes: The two most commonly employed routes (IM and 234 
vaginal) were further analysed to determine if the time at which supplementation 235 
commenced affected pregnancy rates. The comparator group was the “at oocyte retrieval” 236 
group as this included the most study groups and women. Next, the intramuscular and 237 
vaginal routes of progestogen administration were directly compared with vaginal 238 
administration as the comparator group. The data was stratified into the following time 239 
points: before oocyte retrieval, at oocyte retrieval, between oocyte retrieval and ET, at ET 240 
and all times combined (overall).  241 
An additional comparison was performed between the intramuscular and vaginal routes of 242 
administration with the data stratified by publication date as follows: 1990-1999, 2000-243 
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2009 and 2010-2017. There were no studies reporting the use of vaginal progestogen 244 
supplementation prior to 1990.   245 
Determination of the optimal day after oocyte retrieval to start progestogen 246 
supplementation: The database was further interrogated to compare different specific start 247 
times of progestogen supplementation, with the day of oocyte retrieval acting as the 248 
reference. The times categorised were the first, second and third day after oocyte retrieval.  249 
Effect of co-administration of estrogen with progestogen supplementation: The data was 250 
analysed in two separate ways (1) with the data categorised by vaginal, IM or all routes 251 
of administration and (2) with data categorised into “at oocyte retrieval” and “between 252 
oocyte retrieval and embryo transfer”. In all cases, the comparator was the no estrogen 253 
treatment group.  254 
Effect of duration of progestogen supplementation: For this, progestogen supplementation 255 
for 3 weeks and less (the comparator) was compared with more than 3 weeks. Initially, 256 
all routes of administration were included, but this was then stratified according to either 257 
intramuscular or vaginal route of administration.  258 
Results  259 
Characteristics of identified studies  260 
A total of 82 articles (Supplementary Table 1) including 26,726 women met the selection 261 
criteria, which were published between 1983 and 2018. This created 185 different study 262 
groups/treatments. Both prospective and retrospective studies were incorporated into this 263 
analysis. The prospective studies included “randomised control trials” however a large 264 
proportion of these studies did not have a control-untreated group. More often they were 265 
randomised trials in which two or more different treatments were compared. In respect to 266 
live births, there were fewer study groups (N=65) with a lower number of women 267 
(n=12,006). Consequently, live birth rates were considered as a secondary outcome 268 
measure.  269 
The studies were conducted across the World with the greatest proportion of the studies 270 
originating from continental Europe (32%), North America (23%), and the Middle East 271 
(27%). A relatively low percentage of the studies were performed in Asia (13%), the UK 272 
(2%), South America (1%) and Africa (2%).  273 
The youngest reported individual in the dataset was 18 years old, while the oldest was 47. 274 
In the majority of articles, the age groups were matched across the different treatments 275 
and the overall mean age was 32.8 years old. The fertilisation rates and number of 276 
embryos transferred (mean: 3.5) were generally stated but not in all studies. The ovarian 277 
stimulation protocol was described in most study groups, with 132 using long GnRH agonist 278 
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protocols, 10 using a short GnRH agonist flare protocol and 16 with short GnRH antagonist 279 
protocol. However, the induction protocol was not clearly stated in the other study groups 280 
(N=27). A variety of ovarian induction hormones were used within these protocols 281 
including FSH (N=74), HMG (N=19) and both recombinant FSH and HMG (N=42), while 282 
50 study groups did not mention which type of gonadotrophin was used. The most common 283 
treatment used to trigger final oocyte maturation was HCG (N=173), and in the remaining 284 
12 study groups the ovulation trigger was not detailed. 285 
The aetiology of the specific infertility was mentioned in only 5 study groups, where women 286 
were at risk of ovarian hyper-stimulation syndrome (OHSS). Thus, there was insufficient 287 
information to dissect the benefits of progestogen supplementation according to different 288 
underlying pathologies to warrant further investigation.  289 
Risk of bias 290 
Most articles (including those reporting control study groups) were identified as having an 291 
unclear or high risk of bias in one or more domain (Supplementary Fig 2 & 3), often 292 
resulting from a lack of detail reported in the original methods (e.g. if or how 293 
randomisation was generated). Blinding was considered difficult to achieve given the 294 
markedly different routes of administration (vaginal vs intramuscular) but was thought 295 
unlikely to have introduced significant bias, given the objective nature of pregnancy 296 
outcomes and is not expected to have influenced the outcomes.  297 
The potential risk of bias in those articles which included control study groups appeared 298 
broadly similar to that observed across all articles (Supplementary Fig 3). Amongst the 299 
articles reporting control study groups, one (17) was judged to have a high risk of selection 300 
bias relating to one of the treatment groups.  301 
Does progestogen supplementation improve clinical pregnancy rates in women undergoing 302 
fresh IVF cycles?  303 
There was a significant benefit to clinical pregnancy rates of either intramuscular (OR=4.57 304 
[CI: 2.19-9.53]; p<0.001), vaginal (OR=3.34 [CI: 1.61-6.91]; p<0.01), subcutaneous 305 
(OR=3.36 [CI: 1.44-7.83]; p<0.01) or oral (OR=2.57 [CI: 1.19-5.58]; p<0.05) 306 
progestogen supplementation (Fig 1A) versus no treatment. Numerically, this was 307 
equivalent to increasing mean pregnancy rates from 14.7% for untreated women to 30.7% 308 
following oral, 36.4% following vaginal, 36.6% following subcutaneous, and 44.0% 309 
following intramuscular progestogen supplementation. While rectal (OR=2.32 [CI: 0.62-310 
8.68]; p>0.05) routes of administration offered no benefit, although this route was poorly 311 
represented.  312 
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When is the optimal time to start progestogen supplementation? 313 
The relative benefit to clinical pregnancy rates of commencing progestogen 314 
supplementation at different times was compared with no supplementation (Fig 1B). There 315 
was a clear benefit of progestogen supplementation at oocyte retrieval, at embryo transfer 316 
or between these events as well as after embryo transfer. The greatest benefit was clearly 317 
observed when progestogen administration commenced between oocyte retrieval and 318 
embryo transfer (OR=4.76 [CI: 2.35-9.67]; p<0.001). Furthermore, when at oocyte 319 
retrieval and between oocyte retrieval and embryo transfer were directly compared then 320 
there was a clear benefit of starting progesterone administration between oocyte retrieval 321 
and embryo transfer (OR=1.31 [CI: 1.10-1.58], p<0.01). In contrast, there was no benefit 322 
to clinical pregnancy rates versus untreated women when progestogen treatment 323 
commenced before oocyte retrieval (OR=2.10 [CI: 0.95-4.66]; p>0.05).  324 
Does the optimal time to commence progestogen supplementation vary by route of 325 
administration?  326 
In order to address this, the control untreated group was excluded and the different start 327 
times were compared to starting progestogen supplementation at oocyte retrieval. There 328 
were insufficient study groups and women to include the after ET group.  Additionally, 329 
intramuscular and vaginal routes of administration were analysed separately.  330 
When progestogen was administered intramuscularly, starting progestogen 331 
supplementation before oocyte retrieval (OR=0.32 [CI: 0.16-0.63]; p<0.01) was less 332 
favourable to clinical pregnancy rates than administration commencing at oocyte retrieval 333 
(Fig 2A). There was no statistically significant benefit to clinical pregnancy rates of 334 
commencing progestogen supplementation between oocyte retrieval and embryo transfer 335 
(OR=1.30 [CI: 0.97-1.75]; p=0.08) or at embryo transfer (OR=0.75 [CI: 0.44-1.28]; 336 
p>0.05). 337 
When progestogen was administered vaginally, the greatest benefit to clinical pregnancy 338 
rates was observed when administration began between oocyte retrieval and embryo 339 
transfer (OR=1.38 [CI: 1.10-1.74]; p<0.01). While not significant (p>0.05), the odds 340 
ratio for clinical pregnancy rate was numerically lower when starting supplementation 341 
before oocyte retrieval (OR=0.77 [CI: 0.46-1.28]) or at embryo transfer (OR=0.85 [CI: 342 
0.68-1.07] when compared with at oocyte retrieval (Fig 2B).  343 
Thus, it appeared that commencing progestogen supplementation before oocyte retrieval 344 
vaginally was less detrimental to clinical pregnancy rates than following intramuscular 345 
treatment. This indicated that when progestogen was administered intramuscularly or 346 
vaginally, the supplementation start times differentially influenced clinical pregnancy 347 
outcomes.  348 
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In respect to live birth rates, across all routes combined, there was a clear benefit of 349 
commencing supplementation between oocyte retrieval and embryo transfer (OR=1.33 350 
[CI: 1.04-1.69], p<0.05) when compared with at oocyte retrieval (Fig 2C). In contrast, 351 
live birth rates were decreased when progestogen supplementation commenced before 352 
oocyte retrieval (OR=0.52 [CI: 0.30-0.92], p<0.05). However, live birth rates were no 353 
different when progestogen was supplemented at embryo transfer (OR=0.84 [CI: 0.65-354 
1.08]; p>0.05).  355 
Which route of progestogen administration (IM or vaginal) is more beneficial in terms of 356 
clinical pregnancy and live birth rates? 357 
When all time-points were combined for each route, intramuscular progestogen 358 
administration offered the greatest overall benefit to clinical pregnancy rates (OR=1.37 359 
[CI: 1.15-1.63], p<0.001) versus vaginal administration. Furthermore, intramuscular 360 
progestogen supplementation was more beneficial to clinical pregnancy rates than the 361 
vaginal route at oocyte retrieval (OR=1.42 [CI: 1.14-1.76]; p<0.01). Similar patterns 362 
were observed between oocyte retrieval and embryo transfer (OR=1.33 [CI: 0.96-1.85]) 363 
and at embryo transfer (OR=1.24 [CI: 0.68-2.27]) but these failed to reach significance 364 
(p>0.05; Fig 3A). Conversely, when progestogen supplementation commenced before 365 
oocyte retrieval (data not shown), vaginal progestogen administration showed numerically 366 
greater clinical pregnancy rates (OR = 0.59 [CI: 0.427-1.32] but this was not significant 367 
(p>0.05), largely due to a small number of study groups (N=4) in each treatment for this 368 
timeframe.  369 
Over time, the proportion of women enrolled in studies administering progestogens 370 
intramuscularly (versus vaginal) has decreased (Supplementary Table 2). However, in 371 
both the 2000-2009 and 2010-2017 timeframes intramuscular progestogen administration 372 
offered a greater benefit to clinical pregnancy rates versus vaginal treatment (p<0.05). 373 
The data was also analysed to confirm whether intramuscular progestogen 374 
supplementation was also of benefit to live birth rates. Fewer studies reported live birth 375 
rates (in total 10391 women), with intramuscular (N=27, n=2910) and vaginal (N=31, 376 
n=7481) progestogen supplementation having equivalent live birth rates (OR=1.17 [CI: 377 
0.89-1.53]; p>0.05).  378 
What is the optimal day after oocyte retrieval to start progestogen supplementation?  379 
The previous analysis demonstrated that progestogen supplementation was most 380 
beneficial when it commenced between oocyte retrieval and embryo transfer. Thus, further 381 
analysis was performed to determine the exact optimal day within this window. This 382 
included 149 study groups and supplementation by intramuscular, vaginal, oral and 383 
subcutaneous routes. The day of oocyte retrieval was used as the comparator (Fig 3B).  384 
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Commencing progestogen supplementation on the day after oocyte retrieval was most 385 
beneficial in terms of clinical pregnancy rates (OR=1.25 [CI: 1.02-1.54]; p<0.05). Starting 386 
supplementation on the second day after oocyte retrieval had equivalent clinical pregnancy 387 
rates to at oocyte retrieval (OR=1.10 [CI: 0.88-1.36]; p>0.05). In contrast, further 388 
delaying supplementation until the third day (OR=0.66 [CI: 0.50-0.87; p<0.01) reduced 389 
clinical pregnancy rates versus starting at oocyte retrieval (Fig 3B). No significant 390 
differences in live birth rates were detected between the different start days (p>0.05; data 391 
not shown).  392 
Does the addition of estrogen treatment to progestogen supplementation improve clinical 393 
pregnancy rates? 394 
The co-administration of estrogen was of no overall benefit to clinical pregnancy rates 395 
(OR=1.33 [CI: 0.90-1.97; p>0.05]). Furthermore, this lack of benefit was observed when 396 
progestogens were co-administered by either the vaginal (OR=1.40 [CI: 0.84-2.34; 397 
p>0.05) or intramuscular route (OR=1.04 [CI: 0.50-2.14; p>0.05) (Fig 4A). Clinical 398 
pregnancy rates were similar following the addition of estrogen to progestogen 399 
supplementation that commenced at oocyte retrieval (OR=1.29 [CI: 0.72-2.34]; p>0.05) 400 
and between oocyte retrieval and embryo transfer (OR=1.59 [CI: 0.85-2.95]; p>0.05) 401 
(Fig 4B). Similarly, live birth rates were not improved by the addition of estrogen 402 
supplementation (p>0.05; data not shown).  403 
Does the duration of progestogen supplementation effect clinical pregnancy and live birth 404 
rates? 405 
Overall, there was no difference in clinical pregnancy rate when progestogen 406 
supplementation was continued for up to 12 weeks (OR=1.06 [CI: 0.87-1.29]; N=115, 407 
n=17,215; p>0.05) compared with ceasing after 3 weeks (N=41, n=5357). Similarly, if 408 
the duration of progestogen supplementation was categorised into smaller 2 or 3 weekly 409 
intervals, then there was no particular timeframe that was of greater benefit than ceasing 410 
supplementation after three weeks (data not shown). When the data was subdivided based 411 
on route of progestogen supplementation (intramuscular or vaginal) then extending 412 
progestogen supplementation was not beneficial to clinical pregnancy rates when it was 413 
administered intramuscularly (OR=1.23 [CI: 0.85-1.78]; N=17, n=1486 [≤3 weeks] vs 414 
N=29, n=3771 [3-12 weeks]; p>0.05) or vaginally (OR= 0.94 [CI: 0.75-1.19]; N=15, 415 
n=3338 [≤3 weeks] vs N=72, n=10654 [3-12 weeks]; p>0.05).  416 
The dataset was more limited when considering live births. Overall, continuing 417 
progestogen supplementation for >3 weeks similarly had no benefit to live birth rates 418 
(OR=1.11 [CI: 0.88-1.46]; N=17, n=3411 [≤3 weeks] vs N=46, n=8121 [3-12 weeks]; 419 
p>0.05). When the data was subdivided based on whether progestogen supplementation 420 
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was via intramuscular or vaginal routes then extending progestogen supplementation had 421 
no benefit when administered vaginally (OR=1.31 [CI: 0.99-1.74]; N=6, n=2431 [≤3 422 
weeks] vs N=24, n=4878 [3-12 weeks]; p=0.06) or when administered intramuscularly 423 
(OR= 0.72 [CI: 0.43-1.20]; N=10, n=960 [≤3 weeks] vs N=16, n=1648 [3-12 weeks]; 424 
p>0.05). 425 
 426 
Discussion  427 
Progestogen supplementation was of benefit to clinical pregnancy rates when administered 428 
intramuscularly, subcutaneously, orally or vaginally. The best response was observed 429 
when administration commenced at or following oocyte retrieval. The benefit was less 430 
however, if progestogen supplementation was delayed for 2 or more days after oocyte 431 
retrieval, likely reflecting the benefit of exogenous progestogen prior to embryo transfer. 432 
The most commonly reported routes of progestogen supplementation were intramuscular 433 
and vaginal. Both routes improved clinical pregnancy rate versus no treatment, with most 434 
benefit observed following intramuscular administration.  435 
Progestogen supplementation was found to be of some benefit to clinical pregnancy rates, 436 
ongoing pregnancy and live birth versus placebo or no-treatment in a Cochrane review of 437 
875 women across 8 randomised controlled trials (10). Also in that review intramuscular 438 
progestogen was of more benefit than vaginal/rectal (OR=1.24, [CI: 1.03-1.50]) in 439 
respect to live birth rates. However, a difference between these two routes was not 440 
detected when clinical pregnancy rates were considered (13 RCTs, 2932 women). The 441 
present study utilised a distinctive and robust statistical approach, enabling a broad- 442 
ranging scope which incorporates retrospective studies. Importantly, it revealed that 443 
intramuscular progestogen was of greater benefit to clinical pregnancy rates than vaginal 444 
progestogen (153 study groups, 22852 women). This was particularly evident when 445 
administration commenced at oocyte retrieval.  446 
Intramuscular administration offered most benefit to clinical pregnancy rate in the current 447 
study, however, it represented only 26% of treatments, with the majority (62%) of 448 
supported cycles using vaginal administration. In a survey of luteal phase support in 408 449 
treatment centres from 82 countries, vaginal progestogens were administered alone in 450 
77% of supplemented cycles (9). Furthermore, the clinical use of intramuscular 451 
progestogens for the support of assisted reproduction has declined in recent years from 452 
13% to around 5%, although it has traditionally been the most popular form of luteal 453 
support in the United States (9, 15). 454 
Vaginal progestogen preparations may be preferred by patients to intramuscular 455 
preparations (18, 19). Vaginal treatments are reportedly well tolerated, due to their ease 456 
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and relative convenience, whilst patients find the injections painful and report high rates 457 
of irritation at the intramuscular injection site (18). In addition, rare but significant side 458 
effects have been reported following intramuscular luteal support (20-23). Vaginal 459 
progestogens are not free from disadvantages however; they may require multiple daily 460 
applications, can lead to vaginal irritation or discharge in some women (24) and the 461 
preparations may leak which is unpleasant and leads to variable exposure.  462 
The routes of progestogen administration exhibit different pharmacological profiles. Oral 463 
progesterone has very poor bioavailability, does not produce a sustained plasma 464 
progesterone concentration (25), fails to elicit an adequate endometrial secretory response 465 
(26) and produces sedative metabolites (27). In addition, a negative impact on 466 
implantation was observed following oral micronized progesterone versus intramuscular 467 
or vaginal progesterone (28, 29). Administration of the orally effective dydrogesterone led 468 
to clinical pregnancy rates similar to those following intravaginal micronized progesterone 469 
support (30, 31). Recent evidence also suggests that oral dydrogesterone is well tolerated 470 
and is not associated with significant fetal or maternal safety risk (32). Despite this, oral 471 
progesterone has very low current clinical use (9). 472 
Intramuscular administration of progesterone results in higher more sustained serum 473 
levels than vaginal administration, however vaginal regimens undergo rapid absorption to 474 
achieve higher endometrial tissue concentrations (33). This preferential uptake of 475 
progesterone has been described as the “first uterine pass effect”, with direct local 476 
transport of progesterone from vagina to uterus thought to explain the enhanced uterine 477 
concentrations (34).  It has been suggested however, that these raised local progesterone 478 
concentrations may not provide optimal support for ongoing pregnancy (35). Indeed, in 479 
the interim analysis of a recent large-scale randomised control trial evaluating 480 
progesterone replacement in frozen transfer cycles, vaginal progesterone administration 481 
resulted in significantly reduced ongoing pregnancy rates versus intramuscular 482 
supplementation (35), thought to result from early pregnancy loss. Intramuscular 483 
progesterone has been suggested to better support early pregnancy via greater uterine 484 
quiescence (36) and different progestogen formulations may also result in varied 485 
luteotrophic metabolites (37).  486 
In a sub-analysis, it was observed that categorising progestogen dosage into low vs high 487 
within intramuscular or vaginal routes revealed that clinical pregnancy rates were not 488 
affected by dosage in either route (data not shown). This is in agreement with the 489 
Cochrane review (10) which demonstrated no effect of dose on live birth rates when 490 
progestogen was administered vaginally. 491 
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The time at which progestogen treatment began had an impact on its degree of benefit. 492 
This aspect of luteal phase support has received less attention and was not reported on 493 
by van der Linden et al (10). The present study has clearly demonstrated that commencing 494 
luteal support following oocyte retrieval but before embryo transfer provided most benefit 495 
to clinical pregnancy rates, irrespective of route. However, the timing of administration 496 
appeared to be more critical for intramuscular progestogen, where the difference in 497 
response before oocyte retrieval (OR=0.32) was markedly lower than in the window 498 
between oocyte retrieval and embryo transfer (OR=1.30). Similarly, live birth rates were 499 
improved when progestogen supplementation commenced between oocyte retrieval and 500 
embryo transfer compared with commencing at oocyte retrieval. Previous studies (14) 501 
have similarly suggested an ideal window for the initiation of luteal support, between the 502 
evening of oocyte retrieval and day 3, based on a small number of randomised controlled 503 
trials. Others have also suggested that the initiation of intravaginal progestogen is critical 504 
(19), with unfavourable results associated with the early initiation of intravaginal gel. 505 
Furthermore, it has been  suggested that the greater bioavailability of vaginal progestogen 506 
to the endometrium may result in precocious development of the endometrial receptivity 507 
window (19).   508 
In the current study the benefit observed within the window from oocyte retrieval and 509 
embryo transfer, largely resulted from luteal support that began on the first day after 510 
oocyte retrieval (OR=1.25 vs at oocyte retrieval). This delay in the initiation of luteal 511 
support does not reflect current clinical practice, where in a survey of IVF units, 80.1% of 512 
luteal phase support began on the day of oocyte retrieval, whilst in 15.4% of cycles 513 
progestogen began on the day of embryo transfer (9). 514 
The co-administration of estrogen plus progestogen was of no overall benefit to clinical 515 
pregnancy rates (OR=1.33; p>0.05). When routes of progestogen supplementation were 516 
considered separately, clinical pregnancy rates did not benefit from the addition of 517 
estrogen to progestogen co-administered by either the vaginal or intramuscular routes. 518 
Equally, there was no benefit to clinical pregnancy rates of estrogen treatment when 519 
different times of progestogen supplementation were considered.  520 
Progesterone supplementation is considered obligatory following the luteal deficiency 521 
observed in ART. However, whether supplemental estrogen is also required to ameliorate 522 
the effects of declining luteal estradiol remains a matter of debate. Experimental results 523 
in human and non-human primates have suggested that normal endometrial function 524 
requires only low levels of estradiol (38). Despite this, elevated serum and endometrial 525 
estradiol levels following vaginal administration have been suggested to enhance 526 
endometrial thickness and implantation (39), whilst others report that it may be 527 
detrimental to endometrial receptivity (40). Other studies have failed to find a link between 528 
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declining estradiol in early or mid-luteal phase of ART cycles and clinical pregnancy or 529 
miscarriage (41).   530 
No differences in endometrial histology were observed in women following GnRH 531 
downregulation and progesterone replacement, with or without varying doses of estrogen 532 
(42). In contrast, estrogen receptor antagonist treatment delayed endometrial maturation, 533 
suggesting a requirement for luteal phase estradiol (43). In addition, endometrial gene 534 
expression is altered by controlled ovarian stimulation (44, 45) and proteins were 535 
differentially expressed by human endometrial cells in response to high estradiol (46). 536 
There are conflicting clinical reports regarding the value of adding estrogen to luteal 537 
support regimes. Progestogens plus estrogen have been associated with higher clinical 538 
pregnancy rates than progestogens alone (47), although this has varied by route of 539 
administration (48). In contrast other studies have shown no beneficial effect of adding 540 
estrogen (10, 49, 50); indeed adverse effects, such as increased miscarriage, have also 541 
been reported (51). Equally, it is possible that circulating E2 levels following ovarian 542 
stimulation might influence whether further boosting estrogen levels is of benefit (52, 53), 543 
however, analysis of this was not possible due to the lack of reporting of E2 levels.  544 
An important consideration in meta-analysis is the consistency between articles, such as 545 
the quantity I2 (54). In the current study, estimation of I2 was not feasible as within each 546 
statistical comparison there were relatively few articles in which both treatments were 547 
performed. Thus, reporting I2 or Cochran’s Q statistic would be invalid and not 548 
representative of the data presented.  549 
Equally, it is clear from other similar meta-analyses, using different statistical approaches,  550 
that there is often moderate to considerable heterogeneity between studies for a particular 551 
comparison. For example, in the Cochrane review by van der Linden et al (10) I2 was 552 
estimated to be 71% when comparing intramuscular versus vaginal routes and 56% when 553 
comparing the effect of estrogen supplementation. Potential causes of this heterogeneity 554 
include variations in ovarian stimulation and / or treatment protocols employed and the 555 
characteristics of the patient populations within the different articles.  556 
A limitation of the present study was that the number of articles reporting live birth data 557 
was markedly lower than those reporting clinical pregnancy rates. Consequently, the 558 
potential for valid sub-analyses in relation to live birth is more restricted. Another 559 
important consideration is that the different estrogen regimes (start time and route) were 560 
not analysed separately, due to the low number of study groups within each comparison. 561 
It is feasible that the different routes and start time could influence pregnancy outcome 562 
and this warrants further investigation.  563 
 564 
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In a worldwide survey of IVF centres, the majority of luteal phase support was continued 565 
up to 8-10 weeks of gestation (44%) or beyond (28%), despite suggestions that it can be 566 
safely discontinued following a positive HCG test (55, 56) or fetal heart pulsations (57). 567 
The rationale for prolonged progesterone is unclear, given that the luteo-placental shift 568 
causes placental progesterone to dominate from the 8th week of pregnancy (58). The 569 
presence of significant luteotrophic HCG levels by week 5 of pregnancy also lead others to 570 
support suspending progesterone early (59). Indeed, in the current study there was no 571 
benefit to clinical pregnancy rates of continuing treatment beyond 3 weeks OR=1.06 [CI: 572 
0.87-1.29]; p>0.05). Similarly, live birth rates were not improved by prolonged 573 
progesterone (intramuscular; >3 weeks v ≤3 weeks; OR= 1.11). 574 
 575 
Conclusion 576 
Our results have clearly established that progestogen supplementation via the IM route 577 
offers the most benefit to clinical pregnancy. These results demonstrate that the optimal 578 
time to commence supplementation is the day after oocyte retrieval, and that clinical 579 
pregnancy rates were not improved by continued supplementation for greater than 3 580 
weeks or by the additional treatment with estrogens. This lack of improvement occurred 581 
whether the progestogen was administered by the vaginal or intramuscular route.  582 
These outcomes are in contrast to current trends in global clinical practice and collectively 583 
suggest that the clinical approach to luteal phase support may not be delivering optimal 584 
benefits. Therefore this study enables the evidence-based re-evaluation of clinical 585 
protocols for progestogen supplementation, the provision of improved informed choice for 586 
patients and ultimately greater pregnancy success for women undergoing fresh IVF cycles. 587 
 588 
  589 
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Figure captions 770 
 771 
Figure 1: The odds ratio (± 95% confidence intervals) for the relative benefit to clinical 772 
pregnancy of the (A) different routes and (B) start time of progestogen supplementation 773 
versus no progestogen treatment in women undergoing fresh IVF cycles. In (A), 774 
progestogens were administered by intramuscular (IM), oral, rectal, subcutaneous (SC) or 775 
vaginal routes. In (B), the different start times for progestogen supplementation were; 776 
before the day of oocyte retrieval (before OoR); at oocyte retrieval (at OoR); between 777 
oocyte retrieval and the day of embryo transfer (OoR-ET); on the day of embryo transfer 778 
(at ET); after the day of embryo transfer (after ET). The dotted line represents the 779 
comparative odds ratio for the control (untreated) group. Significant differences between 780 
treatment and control are indicated as follows: *, p<0.05; **, p<0.01; ***, p<0.001. N 781 
= number of study groups, n = total number of women, for each treatment or comparator.  782 
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Figure 2: The odds ratio (± 95% confidence intervals) for the relative benefit to clinical 784 
pregnancy of the different times to commence A) intramuscular and B) vaginal 785 
progestogen supplementation, while C) shows the relative benefit to live births of the 786 
different times to commence progestogen supplementation with all routes combined, in 787 
women undergoing fresh IVF cycles. The start times were; before the day of oocyte 788 
retrieval (before OoR); at oocyte retrieval (at OoR); between oocyte retrieval and the day 789 
of embryo transfer (OoR-ET); on the day of embryo transfer (at ET). The dotted line 790 
represents the comparative odds ratio for commencing progestogen at oocyte retrieval 791 
(OoR). Significant differences between treatment and comparator (at OoR) are indicated 792 
as follows: *, p<0.05; **, p<0.01. N = number of study groups, n = total number of 793 
women, for each treatment or comparator.  794 
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 796 
Figure 3: The odds ratio (± 95% confidence intervals) for the relative benefit to clinical 797 
pregnancy of (A) intramuscular versus vaginal progestogen supplementation and (B) 798 
commencing on specific days after oocyte retrieval (OoR) in women undergoing fresh IVF 799 
cycles. In (A), the analysis was split into the different times that treatment began as 800 
follows: at oocyte retrieval (at OoR); between oocyte retrieval and the day of embryo 801 
transfer (OoR-ET); on the day of embryo transfer (at ET); at all start times combined 802 
(Overall). The dotted line represents the comparative odds ratio for vaginal administration 803 
of progestogen. In (B), all routes of administration were included and the different times 804 
were as follows: Oocyte retrieval plus 1 day (OoR +1), plus 2 days (OoR +2) and plus 3 805 
days (OoR +3). The dotted line represents the comparative odds ratio for administration 806 
of progestogen at oocyte retrieval (OoR). Significant differences between treatment and 807 
comparator are indicated as follows: *, p<0.05; **, p<0.01; ***, p<0.001. N = number 808 
of study groups, n = total number of women, for each treatment or comparator. IM, 809 
intramuscular; v, vaginal. 810 
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 812 
Figure 4: The odds ratio (± 95% confidence intervals) for the relative benefit to clinical 813 
pregnancy of combining estrogen and progestogen supplementation in women undergoing 814 
fresh IVF cycles. In A), progestogen was administered by vaginal or intramuscular (IM) 815 
routes and all progestogen routes combined (Overall).  In B), progestogen administration 816 
commenced at oocyte retrieval (OoR) or between oocyte retrieval and embryo transfer 817 
(OoR–ET).  The dotted line represents the comparative odds ratio for progestogen-only 818 
treatment (no estrogen). There were no significant differences between treatment and 819 
comparators. N = number of study groups, n = total number of women, for each treatment 820 
or comparator. +E, plus estrogen; -E, no estrogen. 821 
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 823 
Figure captions – Supplementary 824 
 825 
Supplementary Figure 1: PRISMA (Preferred Reporting Items for Systematic Reviews 826 
and Meta-analyses) 2009 flow diagram. 827 
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 829 
Supplementary Figure 2: Risk of bias summary: review authors' judgements about 830 
each risk of bias item for each included study. Articles including control study groups are 831 
indicated by *.  832 
 833 
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 834 
Supplementary Figure 3: Risk of bias graphs: review authors' judgements about each 835 
risk of bias item presented as percentages across a) all included studies, and b) those 836 
articles which included control study groups. 837 
 838 
  839 
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Supplementary Table 1: Summary and bibliography of the studies 840 
investigating the effects of progestogen supplementation in 841 
women undergoing ART, which met the inclusion criteria and from 842 
which data was extracted. 843 
 844 
 845 
 846 
 847 
 848 
 849 
 850 
 851 
 852 
 853 
 854 
 855 
 856 
 857 
 858 
 859 
 860 
 861 
 862 
 863 
 864 
 865 
 866 
 867 
 868 
 869 
 870 
 871 
 872 
 873 
 874 
 875 
 876 
 877 
 878 
 879 
 880 
 881 
No. Reference Year Region No. of 
women 
No. of study 
groups 
1 Abate, et al. (1) 1999a EUROPE 86 2* 
2 Abate, et al. (2) 1999b EUROPE 156 3* 
3 Abu-Musa, et al. (3) 2008 MIDDLE EAST 125 2 
4 Aghahosseini, et al. (4) 2011 MIDDLE EAST 108 2 
5 Aghsa, et al. (5) 2012 MIDDLE EAST 147 2 
6 Artini, et al. (6) 1995 EUROPE 132 3* 
7 Bahceci and Ulug (7) 2008 MIDDLE EAST 2013 4 
8 Baker, et al. (8) 2014 USA 782 2 
9 Baruffi, et al. (9) 2003 S.AMERICA 103 2 
10 Belaisch-Allart, et al. (10) 1987 EUROPE 258 2* 
11 Ben-Nun, et al. (11) 1990 MIDDLE EAST 111 3* 
12 Bergh and Lindenberg (12) 2012 EUROPE 1983 2 
13 Ceyhan, et al. (13) 2008 MIDDLE EAST 44 2 
14 Chakravarty, et al. (14) 2005 ASIA PACIFIC 430 2 
15 Chantilis, et al. (15) 1999 USA 206 2 
16 Check, et al. (16) 1991 USA 127 2 
17 Costabile, et al. (17) 2001 EUROPE 300 2 
18 Dal Prato, et al. (18) 2008 EUROPE 412 3 
19 Damario, et al. (19) 1999 USA 271 2 
20 Drakakis, et al. (20) 2007 EUROPE 77 2 
21 Elgindy, et al. (21) 2010 MIDDLE EAST 270 3 
22 Engmann, et al. (22) 2008 UK 166 2 
23 Fanchin, et al. (23) 2001 EUROPE 84 2 
24 Farhi, et al. (24) 2000 MIDDLE EAST 285 4 
25 Fatemi, et al. (25) 2006 EUROPE 182 2 
26 Feinberg, et al. (26) 2013 USA 681 2 
27 Friedler, et al. (27) 1999 MIDDLE EAST 64 2 
28 Fujiwara (28) 2015 ASIA PACIFIC 90 2 
29 Ganesh, et al. (29) 2011 ASIA PACIFIC 1363 3 
30 Gao, et al. (30) 2018 ASIA PACIFIC 197 2 
31 Geber, et al. (31) 2007 MIDDLE EAST 244 2 
32 Germond, et al. (32) 2002 EUROPE 114 2 
33 Gorkemli, et al. (33) 2004 MIDDLE EAST 288 2 
34 Goudge, et al. (34) 2010 USA 97 2 
35 Gun, et al. (35) 2016 MIDDLE EAST 177 2 
36 Ho, et al. (36) 2008 ASIA PACIFIC 144 2 
37 Hurd, et al. (37) 1996 USA 79 2* 
38 Ismail Madkour, et al. (38) 2016 USA 220 2 
39 Iwase, et al. (39) 2008 ASIA PACIFIC 40 2 
40 Jabara, et al. (40) 2009 USA 292 2 
41 Kahraman, et al. (41) 2010 MIDDLE EAST 426 2 
42 Khan, et al. (42) 2009 USA 240 4 
43 Khrouf, et al. (43) 2016 AFRICA 186 3 
44 Kleinstein (44) 2005 EUROPE 430 2 
45 Kupferminc, et al. (45) 1990 MIDDLE EAST 105 2* 
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 886 
 887 
 888 
 889 
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 891 
 892 
 893 
 894 
 895 
 896 
 897 
 898 
 899 
 900 
 901 
 902 
 903 
 904 
 905 
  906 
No. Reference Year Region No. of 
women 
No. of study 
groups 
46 Kwon, et al. (46) 2013 ASIA PACIFIC 108 2 
47 Leeton, et al. (47) 1985 ASIA PACIFIC 186 3* 
48 Lewin, et al. (48) 1994 MIDDLE EAST 100 2 
49 Licciardi, et al. (49) 1999 USA 43 2 
50 Lin, et al. (50) 2013 ASIA PACIFIC 402 4 
51 Lockwood, et al. (51) 2014 UK 640 2 
52 Ludwig and Diedrich (52) 2001 EUROPE 126 2 
53 Lukaszuk, et al. (53) 2005 EUROPE 224 3 
54 Michnova, et al. (54) 2017 EUROPE 100 2 
55 Mitwally, et al. (55) 2010 USA 544 2 
56 Mochtar, et al. (56) 2006 EUROPE 298 3 
57 Moini, et al. (57) 2011a MIDDLE EAST 98 2 
58 Moini, et al. (58) 2011b MIDDLE EAST 153 3 
59 Papaleo, et al. (59) 2010 EUROPE 172 2 
60 Perino, et al. (60) 1997 EUROPE 300 2 
61 Pouly, et al. (61) 1996 EUROPE 283 2 
62 Proctor, et al. (62) 2006 USA 358 2 
63 Propst, et al. (63) 2001 USA 201 2 
64 Saharkhiz, et al. (64) 2015 MIDDLE EAST 210 2 
65 Salehpour, et al. (65) 2013 MIDDLE EAST 80 2 
66 Schoolcraft, et al. (66) 2000 USA 89 2 
67 Serna, et al. (67) 2008 EUROPE 160 2 
68 Silverberg, et al. (68) 2012 USA 474 2 
69 Simunic, et al. (69) 2007 EUROPE 266 2 
70 Smitz, et al. (70) 1992 EUROPE  262 2 
71 Smitz, et al. (71) 1993 EUROPE 378 2 
72 Sofuoglu, et al. (72) 2015 MIDDLE EAST 463 2 
73 Sohn, et al. (73) 1999 USA 282 2 
74 Stadtmauer, et al. (74) 2013 USA 1297 2 
75 Tomic, et al. (75) 2015 EUROPE 831 2 
76 Tonguc, et al. (76) 2011 MIDDLE EAST 285 3 
77 Tournaye, et al. (77) 2017 EUROPE 967 2 
78 Unfer, et al. (78) 2004a EUROPE 734 2 
79 Unfer, et al. (79) 2004b EUROPE 284 2 
80 Wang, et al. (80) 2009 ASIA PACIFIC 460 2 
81 Williams, et al. (81) 2001 USA 126 2 
82 Yanushpolsky, et al. (82) 2010 USA 407 2 
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Supplementary Table 2: The relative benefit to clinical pregnancy between 907 
intramuscular and vaginal progestogen supplementation in women undergoing fresh IVF 908 
cycles, stratified by decade. 909 
Decade Number of study groups (N), 
number of women (n); pregnancy 
rate 
Odds ratio1  
(95% CI) 
P-value 
1990-1999 
N=21, n=2379; 32.3% (vaginal) 
1.27 (0.94-1.71) ns 
N=23, n=2277; 36.8% (IM) 
2000-2009 
N=58, n=11086; 39.4% (vaginal) 
1.38 (1.07-1.79) p<0.05 
N=18, n=3289; 44.3% (IM) 
2010-2017 
N=21, n=2601; 33.2% (vaginal) 
2.33 (1.62-3.35) p<0.001 
N=10, n=1114; 51.2% (IM) 
1reference route of administration is vaginal. IM: intramuscular 910 
 911 
 912 
 913 
